Rapid health technology assessment of six non-ergot dopamine-receptor agonists for the treatment of early Parkinson’s disease
Based on our comprehensive multi-criteria assessment, pramipexole ER, pramipexole IR, rotigotine patch, and piribedil are strongly recommended for inclusion in the formularies of medical institutions as therapeutic options for patients with early PD.
Authors
- Sha Lai
- Jieqiong Lv (ORCID: https://orcid.org/0000-0001-7100-5173)
- Hongbo Fu
- Jiaxin Zhang (ORCID: https://orcid.org/0000-0002-1432-6584)
- Zhihua Zhou (ORCID: https://orcid.org/0000-0001-5014-6946)
- Wenwei Li (ORCID: https://orcid.org/0000-0001-6286-2851)
- Yanqiong Zhou
Institutions
- Shantou University (CN)
- Integrated Chinese Medicine (China) (HK)
- First Affiliated Hospital of Guangdong Pharmaceutical University (CN)
- Second Affiliated Hospital of Shantou University Medical College (CN)
Publication Details
- Journal
- Frontiers in Pharmacology
- Published
- 2025-12-17
- DOI
- https://doi.org/10.3389/fphar.2025.1648833
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00